Events

Oncoinvent to present at DNB Nordic Healthcare Conference 2019

Oncoinvent CEO, Jan A. Alfheim will present the company at the DnB Nordic Healthcare Conference 2019 at the venture session for scaleups.

Organiser: DnB
Venue: Audioturium 1

Dronning Eufemias gate 30,

Oslo, Norway


Date: December 12, 2019 3:35 pm
Program

Oncoinvent to present at Nordic American Life Science Conference 2019

Oncoinvent CEO, Jan A. Alfheim will present the company at the Nordic American Life Science Conference in New York, USA 

Organiser: Nasdaq, DNB, Business Sweden
Venue: Well Said, Convene, 151 West 42nd Street, New York, NY 10036
Date: December 5, 2019 2:30 pm
Program

Invitation to a Presentation of the Third Quarter 2019 Results

Oncoinvent would like to extend an invitation to a presentation of the Q3 2019 results. The presentation will be held at 14:00 on Thursday 31. October 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor.

To attend, please register with 

kvam@oncoinvent.com

The quarterly report will be made available on www.oncoinvent.com on the 31. October 2019

Organiser: Oncoinvent AS
Venue: Gullhaugsveien 7, Oslo
Date: October 31, 2019 2:00 pm
Program

Outsourcing in Clinical Trials and Clinical Trial Supply Nordics

Head of Clinical Operations at Oncoinvent, Helen Johansen Blanco will be presenting at the conference “Outsourcing in Clinical Trials and Clinical Trial Supply Nordics”.

Organiser: Arena Event International
Venue: Scandic Copenhagen, Denmark  
Date: October 22, 2019 3:00 pm
Program

European Association of Nuclear Medicine (EANM) 2019

CSO Tina Bønsdorff, presented the ePoster «Feasibility of Ra-224 SPECT CT imaging in a therapeutic setting – a phantom study» developed by Stokke (PhD, Assoc. Prof) and Mikalsen (PhD) at Oslo University Hospital, Oslo, NORWAY, at the European Association of Nuclear Medicine (EANM) annual conference held in Barcelona.

Organiser: European Association of Nuclear Medicine (EANM)
Venue: CCIB – Centre de Convencions Internacional de Barcelona, Placa de Willy Brandt, 11-14 08019 Barcelona, Spain
Date: October 16, 2019 12:00 am
Program

Presentation of the Second Quarter 2019 Results

Oncoinvent would like to extend an invitation to a presentation of the Q2 2019 results. The presentation will be held at 15:00 on Thursday 29. August 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor.

Going forward quarterly result presentations will be held on a regular basis.

To attend, please register with
kvam@oncoinvent.com

The quarterly report will be made available on www.oncoinvent.com on the 29. August 2019

Organiser: Oncoinvent AS
Venue: Gullhaugsveien 7, Oslo
Date: August 29, 2019 3:00 pm
Program

Oncoinvent to present poster at the SNMMI 2019 Annual Meeting

Oncoinvent researcher Elisa Napoli will present the poster “A primary activity standard for the alpha-emitting radionuclide Ra-224” at the SNMMI 2019 Annual Meeting.

Organiser: Society of Nuclear Medicine & Molecular Imaging
Venue: SNMMI 2019 Annual Meeting, Anaheim, CA
Date: June 25, 2019 12:00 am
Program

Oncoinvent to present at ABGSC Norwegian Biotech Oncology Seminar

Jan A. Alfheim, CEO of Oncoinvent will give a short status presentation about the company at the ABG Sundal Collier’s Norwegian Biotech Oncology Seminar

Organiser: ABGSC
Venue: ABG Sundal Collier, Munkedamsveien 45E, 7th floor, Oslo, Norway
Date: June 11, 2019 11:00 am
Program

Oncoinvent to present at International Cancer Cluster Showcase

Oncoinvent CEO Jan A. Alfheim will be presenting the company during the International Cancer Cluster Showcase at the BIO International Convention 2019.

Organiser: BIO International
Venue: BIO International, Pennsylvania Convention Center, Room : 204B, level 200, 1101 Arch St, Philadelphia, PA 10107, USA
Date: June 3, 2019 12:00 am
Program

Oncoinvent to present at the Venture Session of DNB’s 8th Annual Nordic Healthcare Conference 2017

Oncoinvent CEO Jan A. Alfheim will be presenting at 10:25 during the morning Venture Session on Thursday the 14th of December

Organiser: DnB
Venue: DNB Bank, Dronning Eufemias Gate 30, Bjørvika, 0191 Oslo, Norway
Date: December 14, 2017 8:30 am
Program

Oncoinvent to present preclinical efficacy data in a poster session at the 20th Biennial Meeting of the European Society of Gynaecological Oncology (ESGO 2017)

The poster ‘Preclinical Evaluation of a Novel Alpha-Particle Emitting Therapeutic Agent for Intraperitoneal Therapy of Peritoneal Metastases’ by Oncoinvent scientists Tina B. Bønsdorff, Sara Westrøm, Øyvind S. Bruland and Roy H. Larsen will be presented at the congress.

Organiser: ESGO
Venue: Austria Center Vienna, Bruno Kreisky Platz 1, Vienna, 1210 Austria
Date: November 4, 2017 9:30 am
Program

Oncoinvent to present at the 30th Annual Congress of the European Association of Nuclear Medicine – EANM

Researchers Sara Westrøm and Elisa Napoli will each be presenting findings of their research during the morning session on Sunday the 22nd of October

Organiser: EANM
Venue: Austria Center Vienna, Bruno Kreisky Platz 1,Vienna, 1210 Austria
Date: October 21, 2017 8:00 am

Oncoinvent Update – Radforsk Podcast

Oncoinvent CEO Jan A. Alfheim speaks with Radforsk’s Jónas Einarsson and Elisabeth Kirkeng Andersen

Organiser: RADFORSK
Venue: Ullernchausséen 64 – 66, 0379 Oslo, Norway
Date: October 18, 2017 12:00 am
Program

Oncoinvent to present at Partnership4Life Symposium

CEO Jan A. Alfheim will give a company presentation at the upcoming Partnership4Life symposium on February 15.

Organiser: The Life Science Cluster
Venue: Forskningsparken, Gaustadaléen 21 Oslo, Norge
Date: February 15, 2017 12:00 pm
Program

DNB Health Care Conference

Organiser:
Venue: DNB BANK, Dronning Eufemiasgate 30, Bjørvika, NO- 0191 Oslo
Date: December 15, 2016 8:30 am
Program

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.